3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Wilms Tumor
1
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Medulloblastoma
1
Glioma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
3
Filgrastim
2
Drug Therapy
2
talazoparib
1
sargramostim
1
pembrolizumab
1
oblimersen
1
irinotecan sucrosofate
1
etoposide phosphate
1
entrectinib
1
atezolizumab
1
X-Rays
1
Vincristine
1
Specimen Handling
1
Radiotherapy
1
Radiosurgery
1
Proteasome Inhibitors
1
Platinum
1
Phantoms, Imaging
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Monatide (IMS 3015)
1
Microarray Analysis
1
Lenalidomide
1
Isotretinoin
1
Irinotecan
1
Immunomodulating Agents
1
Immunohistochemistry
1
Ifosfamide
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Wilms Tumor
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA